New Study Suggests GLP-1 Medications May Lower Risk of Obesity-Related Cancers

Cleveland, Ohio, Ohio, USA United States of America
GLP-1 medications include Ozempic and Wegovy.
GLP-1 treatment not associated with reduced risk of postmenopausal breast cancer or stomach or thyroid cancers.
New study suggests GLP-1 medications may lower risk of obesity-related cancers.
People with type 2 diabetes on GLP-1 treatment had a significantly lower risk of 10 out of 13 obesity-associated cancers compared to those on insulin.
Reduced risk significant for gallbladder cancer, meningioma, pancreatic cancer, hepatocellular carcinoma (a kind of liver cancer), ovarian cancer, colorectal cancer, multiple myeloma, esophageal cancer and endometrial cancer.
The research was published in JAMA Network Open.
New Study Suggests GLP-1 Medications May Lower Risk of Obesity-Related Cancers

A new study suggests that GLP-1 medications, including Ozempic and Wegovy, may help lower the risk of certain obesity-related cancers. The research, published in the journal JAMA Network Open, found that people with type 2 diabetes who were being treated with these drugs had a significantly lower risk of developing 10 out of 13 obesity-associated cancers compared to those taking insulin. The reduced risk was significant for gallbladder cancer, meningioma, pancreatic cancer, hepatocellular carcinoma (a kind of liver cancer), ovarian cancer, colorectal cancer, multiple myeloma, esophageal cancer, and endometrial cancer. The study also found that GLP-1 treatment was not associated with a reduced risk of postmenopausal breast cancer or stomach or thyroid cancers. However, it is important to note that the findings do not prove causation and more research is needed to understand how reduced cancer risk may relate to the scale of weight loss.

GLP-1 medications interact with systems related to insulin production and have been shown in other trials to compare favorably with intensive lifestyle intervention and metabolic-bariatric surgery for reducing cancer risk. However, they were not associated with a reduced risk of kidney cancer when compared to metformin treatment.

Obesity is a significant risk factor for at least 13 types of cancer, and the longer a person is overweight or obese, the higher their risk. About 40% of new cancer diagnoses are associated with excess weight. The CDC reports that in 2021, there were about 170 new diagnoses for every 100,000 people.

Excess weight can cause changes in the body such as long-lasting inflammation and higher than normal levels of insulin, insulin-like growth factor and sex hormones that can contribute to cancer. GLP-1 medications interact with these systems and may help reduce cancer risk by lowering inflammation, improving insulin sensitivity, and reducing the production of certain growth factors.

The study authors note that further preclinical and clinical studies are needed to confirm the potential benefits of GLP-1RAs for cancer prevention in high-risk populations.


Article Image
Article Image
Article Image
Article Image
Article Image
Article Image
Article Image
Article Image

Confidence

90%

Doubts
  • Are there any non-peer reviewed studies that could affect these findings?

Sources

100%

The overall score is a weighted number that takes into account conflict of interest, bias, deception and other practices that undermine the credibility of the source. It is calculated as:
(Site Conflicts Of Interest + Author Conflicts Of Interest) / 2.0 * 0.2 + ArticleBiasScore * 0.20 + UniquePointsScore * 0.05 + DeceptionScore * 0.20 + ReadabilityScore * 0.05 + FallacyScore * 0.20

A score that takes into consideration the content for flow, interruptions with ads, and overt search engine optimization techniques that makes the content hard to understand

Popular weight-loss and diabetes medications linked to lower risk of some cancers, study finds

CNN News Site: In-Depth Reporting and Analysis with Some Financial Conflicts and Sensational Language Deidre McPhillips Saturday, 06 July 2024 00:40
  • Unique Points
    • People who are overweight or obese have a higher risk of getting 13 types of cancer, and the risk increases the longer they are overweight.
    • , About 40% of new cancer diagnoses are associated with excess weight, according to the US Centers for Disease Control and Prevention.
    • People treated with GLP-1 drugs had significantly lower risk of gallbladder cancer, meningioma, pancreatic cancer and hepatocellular carcinoma.
    • , Risk was also significantly reduced for ovarian cancer, colorectal cancer, multiple myeloma, esophageal cancer and endometrial cancer.
  • Accuracy
    No Contradictions at Time Of Publication
  • Deception (100%)
    None Found At Time Of Publication
  • Fallacies (100%)
    None Found At Time Of Publication
  • Bias (100%)
    None Found At Time Of Publication
  • Site Conflicts Of Interest (100%)
    None Found At Time Of Publication
  • Author Conflicts Of Interest (100%)
    None Found At Time Of Publication

99%

The overall score is a weighted number that takes into account conflict of interest, bias, deception and other practices that undermine the credibility of the source. It is calculated as:
(Site Conflicts Of Interest + Author Conflicts Of Interest) / 2.0 * 0.2 + ArticleBiasScore * 0.20 + UniquePointsScore * 0.05 + DeceptionScore * 0.20 + ReadabilityScore * 0.05 + FallacyScore * 0.20

A score that takes into consideration the content for flow, interruptions with ads, and overt search engine optimization techniques that makes the content hard to understand

Diabetes drugs like Ozempic lower cancer risks: Study

MedicalXpress Science X Saturday, 06 July 2024 11:40
  • Unique Points
    • A study published in the journal JAMA found that patients with Type 2 diabetes who were given GLP-1 agonists, including Ozempic, had a significantly lower risk of developing 10 out of 13 obesity-related cancers.
    • GLP-1 agonists were associated with a lower risk of kidney, pancreatic, esophageal, ovarian, liver and colorectal cancer.
    • No significant change in risk was found for thyroid cancer and breast cancer in postmenopausal women.
  • Accuracy
    • ]A study published in the journal JAMA found that patients with Type 2 diabetes who were given GLP-1 agonists, including Ozempic, had a significantly lower risk of developing 10 out of 13 obesity-related cancers.[
    • People who are overweight or obese have a higher risk of getting 13 types of cancer, and the risk increases the longer they are overweight.
  • Deception (100%)
    None Found At Time Of Publication
  • Fallacies (100%)
    None Found At Time Of Publication
  • Bias (100%)
    None Found At Time Of Publication
  • Site Conflicts Of Interest (100%)
    None Found At Time Of Publication
  • Author Conflicts Of Interest (100%)
    None Found At Time Of Publication

99%

The overall score is a weighted number that takes into account conflict of interest, bias, deception and other practices that undermine the credibility of the source. It is calculated as:
(Site Conflicts Of Interest + Author Conflicts Of Interest) / 2.0 * 0.2 + ArticleBiasScore * 0.20 + UniquePointsScore * 0.05 + DeceptionScore * 0.20 + ReadabilityScore * 0.05 + FallacyScore * 0.20

A score that takes into consideration the content for flow, interruptions with ads, and overt search engine optimization techniques that makes the content hard to understand

Ozempic and Related Drugs May Reduce Cancer Risks, Study Claims

Newsweek LLC Isabel Cameron Friday, 05 July 2024 15:00
  • Unique Points
    • A new study suggests that Ozempic and similar medications may reduce the risk of obesity-related cancers more effectively than other types of weight loss and diabetes drugs.
    • ,
  • Accuracy
    No Contradictions at Time Of Publication
  • Deception (100%)
    None Found At Time Of Publication
  • Fallacies (95%)
    No dichotomous depictions or appeals to authority were found. There are some potential logical fallacies related to overgeneralization and hasty generalizations based on limited data. The author makes claims about Ozempic reducing cancer risks without mentioning possible side effects or long-term consequences of the drug.
    • Individuals taking Ozempic and other drugs belonging to the class known as glucagon-like peptide 1 (GLP-1) have a reduced risk of being diagnosed with 10 out of 13 cancers associated with obesity.
    • Researchers from Case Western Reserve University School of Medicine analyzed health records of over a million people with type 2 diabetes who were treated with insulin, metformin, or GLP-1 drugs. Their findings revealed that patients on GLP-1 drugs had the lowest risk of developing obesity-related cancers.
    • The study utilized a database of electronic health records (EHRs) from 113 million U.S. patients.
  • Bias (100%)
    None Found At Time Of Publication
  • Site Conflicts Of Interest (100%)
    None Found At Time Of Publication
  • Author Conflicts Of Interest (100%)
    None Found At Time Of Publication